Cases & Deals

Celgene buys Gloucester Pharmaceuticals for $640 million to bolster its anticancer drug pipeline

Clients Celgene Corporation

Jones Day advised Celgene Corporation in its acquisition of Gloucester Pharmaceuticals. The acquisition will aid in the development of disease-altering therapies through innovative approaches for patients with rare and debilitating blood cancers. Under the terms of the merger agreement, Celgene will acquire Gloucester Pharmaceuticals for $340 million in cash plus $300 million in future U.S. and international regulatory milestone payments.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.